Multi-API Ophthalmic Compositions for Eye Drop Compliance
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing eye treatments for conditions such as glaucoma, post-op care after eye surgeries, and dry eyes often require multiple medications, leading to patient compliance issues, increased costs, and exposure to preservatives.
Innovation Solution
Development of pharmaceutical compositions combining multiple active pharmaceutical ingredients (APIs) in a single delivery device, such as eye drops or injections, to improve compliance, reduce costs, and minimize side effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If multiple separate eye drop packages are used to treat different eye conditions, then treatment efficacy is maintained, but patient compliance decreases and cost increases
Solution Approach 1:
The patent combines multiple eye drop medications (e.g., timolol for glaucoma, brimonidine for glaucoma, dorzolamide for glaucoma, and latanoprost for glaucoma) into a single multi-component ophthalmic composition delivered through one bottle. This merging approach maintains treatment efficacy by including all necessary APIs while improving patient compliance by eliminating the need to manage multiple separate bottles and application routines.
Solution Approach 2:
The single ophthalmic composition is designed to treat multiple eye conditions simultaneously through its multi-API formulation. The composition can treat glaucoma (via timolol, brimonidine, dorzolamide, latanoprost), post-operative eye conditions (via dexamethasone, moxifloxacin, ketorolac), and other ocular issues, making one product serve multiple therapeutic functions and reducing the need for multiple specialized treatments.
2Adaptability or versatility
If multiple separate eye drop packages are used, then comprehensive treatment coverage is achieved, but patient cost increases
Solution Approach 1:
The patent consolidates multiple medications that would traditionally require separate bottles into a single combined ophthalmic composition. By merging timolol, brimonidine, dorzolamide, latanoprost, dexamethasone, moxifloxacin, and ketorolac into one formulation, the invention reduces the total number of products a patient must purchase and pay for, directly lowering patient cost while maintaining comprehensive treatment coverage.
Solution Approach 2:
The multi-API composition provides universal treatment coverage for various eye conditions including glaucoma, post-operative care needs, and other ocular issues. This multi-functionality allows one product to replace multiple specialized treatments, reducing the cumulative cost of therapy while maintaining adaptability to different patient needs and conditions.
3Reliability
If multiple separate eye drop packages are used, then specific targeted treatment is provided, but exposure to preservatives increases
Solution Approach 1:
The patent combines multiple medications into a single ophthalmic composition that uses a shared preservative system. Instead of multiple separate bottles each with their own preservatives (increasing total exposure), the combined formulation uses one preservative system that serves all APIs, thereby reducing the cumulative preservative exposure to the eye while maintaining specific targeted treatment through the multi-API formulation.
Data Source
AI summary
Pharmaceutical compositions, methods for treating various issues of the eyes, and methods of preparing such compositions are described. These pharmaceutical compositions may be for treating glaucoma, in preparation of eye surgery, during eye surgery, various post-op care (e.g., after cataract surgery, laser eye surgery, and the like), for treating dry eyes, and/or for promoting eyelash growth. These pharmaceutical compositions may comprise such active ingredients (APIs) as: timolol, latanoprost, brimonidine tartrate, dorzolamide, moxifloxacin HCl, dexamethasone PO4, phenylephrine HCl, lidocaine HCl, ketorolac tromethamine, bromfenac, prednisolone PO4, gatifloxacin, amniotic cytokine extract (ACE), prostaglandin E2 (PGE2), and combinations thereof.